Edwards Lifesciences Corporation $EW Stock Position Cut by Machina Capital S.A.S.

Machina Capital S.A.S. decreased its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 54.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 22,727 shares of the medical research company’s stock after selling 26,984 shares during the period. Machina Capital S.A.S.’s holdings in Edwards Lifesciences were worth $1,767,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in the stock. Vanguard Group Inc. raised its holdings in Edwards Lifesciences by 1.2% during the second quarter. Vanguard Group Inc. now owns 69,997,629 shares of the medical research company’s stock worth $5,474,515,000 after purchasing an additional 798,801 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Edwards Lifesciences by 8.1% during the 3rd quarter. Bank of New York Mellon Corp now owns 19,010,227 shares of the medical research company’s stock valued at $1,478,425,000 after purchasing an additional 1,423,365 shares in the last quarter. Jennison Associates LLC increased its position in shares of Edwards Lifesciences by 19.6% during the 3rd quarter. Jennison Associates LLC now owns 13,958,774 shares of the medical research company’s stock valued at $1,085,574,000 after purchasing an additional 2,287,783 shares during the period. Geode Capital Management LLC raised its stake in shares of Edwards Lifesciences by 0.4% in the 2nd quarter. Geode Capital Management LLC now owns 12,722,416 shares of the medical research company’s stock worth $990,074,000 after buying an additional 45,555 shares in the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its stake in shares of Edwards Lifesciences by 111.2% in the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 9,129,357 shares of the medical research company’s stock worth $714,006,000 after buying an additional 4,805,819 shares in the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts recently issued reports on EW shares. Stifel Nicolaus set a $110.00 target price on Edwards Lifesciences and gave the stock a “buy” rating in a report on Tuesday, January 20th. Weiss Ratings restated a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Wednesday, January 21st. JPMorgan Chase & Co. upgraded shares of Edwards Lifesciences from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $90.00 to $100.00 in a report on Thursday, December 18th. TD Cowen raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a research note on Friday, January 9th. Finally, Mizuho raised their target price on shares of Edwards Lifesciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a report on Friday, October 31st. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Edwards Lifesciences presently has an average rating of “Moderate Buy” and a consensus target price of $96.77.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 11,340 shares of Edwards Lifesciences stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $85.66, for a total transaction of $971,384.40. Following the completion of the sale, the vice president owned 31,870 shares of the company’s stock, valued at $2,729,984.20. This trade represents a 26.24% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, VP Daniel J. Lippis sold 1,019 shares of the company’s stock in a transaction on Friday, January 9th. The stock was sold at an average price of $85.70, for a total transaction of $87,328.30. Following the completion of the transaction, the vice president directly owned 22,002 shares in the company, valued at $1,885,571.40. This trade represents a 4.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 57,824 shares of company stock worth $4,863,323. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Price Performance

Shares of NYSE:EW opened at $79.75 on Thursday. The company’s fifty day moving average is $84.48 and its two-hundred day moving average is $81.10. The company has a market cap of $46.28 billion, a P/E ratio of 34.38, a price-to-earnings-growth ratio of 3.16 and a beta of 0.94. Edwards Lifesciences Corporation has a 12-month low of $65.94 and a 12-month high of $87.89. The company has a quick ratio of 3.29, a current ratio of 4.00 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.